Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2-STAT3 signaling pathway

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 6, 2012, Pages 858-869

  Das, Anindita ^a   Salloum, Fadi N ^a   Durrant, David ^a   Ockaili, Ramzi ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Apoptosis; Cardiomyocytes; Infarct size; Myocardial ischemia reperfusion; STAT3

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; RAPAMYCIN; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; JANUS KINASE 2; MALE; MICE; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SIROLIMUS; STAT3 TRANSCRIPTION FACTOR;

MURINAE; MUS;

EID: 84869081320     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.09.007     Document Type: Article

References (60)

1. Morris R.E. Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action. Ann N Y Acad Sci 1993, 685:68-72.
2. Delgado J.F., Manito N., Segovia J., Almenar L., Arizon J.M., Camprecios M., et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev (Orlando) 2009, 23:69-79.
3. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban H.E., Perin M., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780.
4. Jonassen A.K., Sack M.N., Mjos O.D., Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001, 89:1191-1198.
5. Kis A., Yellon D.M., Baxter G.F. Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol 2003, 35:1063-1071.
6. Zhai P., Sciarretta S., Galeotti J., Volpe M., Sadoshima J. Differential roles of GSK-3beta during myocardial ischemia and ischemia/reperfusion. Circ Res 2011, 109:502-511.
7. Khan S., Salloum F., Das A., Xi L., Vetrovec G.W., Kukreja R.C. Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J Mol Cell Cardiol 2006, 41:256-264.
8. Buss S.J., Muenz S., Riffel J.H., Malekar P., Hagenmueller M., Weiss C.S., et al. Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol 2009, 54:2435-2446.
9. Boengler K., Hilfiker-Kleiner D., Drexler H., Heusch G., Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 2008, 120:172-185.
10. Bolli R., Stein A.B., Guo Y.R., Wang O.L., Rokosh G., Dawn B., et al. A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J Mol Cell Cardiol 2011, 50:589-597.
11. Xuan Y.T., Guo Y., Han H., Zhu Y., Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci U S A 2001, 98:9050-9055.
12. Dawn B., Xuan Y.T., Guo Y., Rezazadeh A., Stein A.B., Hunt G., et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 2004, 64:61-71.
13. Myers M.G. Cell biology. Moonlighting in mitochondria. Science 2009, 323:723-724.
14. Suleman N., Somers S., Smith R., Opie L.H., Lecour S.C. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 2008, 79:127-133.
15. Hilfiker-Kleiner D., Hilfiker A., Fuchs M., Kaminski K., Schaefer A., Schieffer B., et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004, 95:187-195.
16. Jacoby J.J., Kalinowski A., Liu M.G., Zhang S.S., Gao Q., Chai G.X., et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci U S A 2003, 100:12929-12934.
17. Boengler K., Buechert A., Heinen Y., Roeskes C., Hilfiker-Kleiner D., Heusch G., et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008, 102:131-135.
18. Gross E.R., Hsu A.K., Gross G.J. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 2006, 291:H827-H834.
19. Boengler K., Hilfiker-Kleiner D., Heusch G., Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 2010, 105:771-785.
20. Heusch G., Musiolik J., Gedik N., Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011, 109:1302-1308.
21. Wegrzyn J., Potla R., Chwae Y.J., Sepuri N.B., Zhang Q., Koeck T., et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.
22. Szczepanek K., Chen Q., Derecka M., Salloum F.N., Zhang Q., Szelag M., et al. Mitochondrial-targeted signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species. J Biol Chem 2011, 286:29610-29620.
23. Das A., Salloum F.N., Xi L., Rao Y.J., Kukreja R.C. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2009, 296:H1236-H1243.
24. Salloum F.N., Abbate A., Das A., Houser J.E., Mudrick C.A., Qureshi I.Z., et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 2008, 294:H1398-H1406.
25. Das A., Xi L., Kukreja R.C. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005, 280:12944-12955.
26. Das A., Xi L., Kukreja R.C. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 2008, 283:29572-29585.
27. Barry S.P., Townsend P.A., McCormick J., Knight R.A., Scarabelli T.M., Latchman D.S., et al. STAT3 deletion sensitizes cells to oxidative stress. Biochem Biophys Res Commun 2009, 385:324-329.
28. Fuglesteg B.N., Tiron C., Jonassen A.K., Mjos O.D., Ytrehus K. Pretreatment with insulin before ischaemia reduces infarct size in Langendorff-perfused rat hearts. Acta Physiol (Oxf) 2009, 195:273-282.
29. Hausenloy D.J., Mocanu M.M., Yellon D.M. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 2004, 63:305-312.
30. Hernandez G., Lal H., Fidalgo M., Guerrero A., Zalvide J., Force T., et al. A novel cardioprotective p38-MAPK/mTOR pathway. Exp Cell Res 2011, 317:2938-2949.
31. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
32. Boluyt M.O., Zheng J.S., Younes A., Long X., O'Neill L., Silverman H., et al. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. Circ Res 1997, 81:176-186.
33. Gao X.M., Wong G., Wang B., Kiriazis H., Moore X.L., Su Y.D., et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens 2006, 24:1663-1670.
34. McMullen J.R., Sherwood M.C., Tarnavski O., Zhang L., Dorfman A.L., Shioi T., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
35. Shioi T., McMullen J.R., Tarnavski O., Converso K., Sherwood M.C., Manning W.J., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107:1664-1670.
36. Zhang D., Contu R., Latronico M.V., Zhang J., Rizzi R., Catalucci D., et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest 2010, 120:2805-2816.
37. Aoyagi T., Kusakari Y., Xiao C.Y., Inouye B.T., Takahashi M., Scherrer-Crosbie M., et al. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2012, 303:H75-H85.
38. Fischer P., Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol 2007, 102:393-411.
39. Smith R.M., Suleman N., Lacerda L., Opie L.H., Akira S., Chien K.R., et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 2004, 63:611-616.
40. Negoro S., Kunisada K., Tone E., Funamoto M., Oh H., Kishimoto T., et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 2000, 47:797-805.
41. 2+ channels in chicken nodose neurons. J Neurochem 2009, 108:246-259.
42. Wierenga A.T., Vogelzang I., Eggen B.J., Vellenga E. Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway. Exp Hematol 2003, 31:398-405.
43. Nguyen-Jackson H., Panopoulos A.D., Zhang H., Li H.S., Watowich S.S. STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and via modulation of CXCR2 signal transduction. Blood 2010, 115:3354-3363.
44. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007, 67:2497-2507.
45. Murphy E., Steenbergen C. Inhibition of GSK-3beta as a target for cardioprotection: the importance of timing, location, duration and degree of inhibition. Expert Opin Ther Targets 2005, 9:447-456.
46. Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004, 113:1535-1549.
47. Juhaszova M., Zorov D.B., Yaniv Y., Nuss H.B., Wang S., Sollott S.J. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009, 104:1240-1252.
48. Ali A., Hoeflich K.P., Woodgett J.R. Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 2001, 101:2527-2540.
49. Hetman M., Hsuan S.L., Habas A., Higgins M.J., Xia Z. ERK1/2 antagonizes glycogen synthase kinase-3beta-induced apoptosis in cortical neurons. J Biol Chem 2002, 277:49577-49584.
50. Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006, 21:749-760.
51. Hardt S.E., Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 2002, 90:1055-1063.
52. + channels. Proc Natl Acad Sci U S A 2012, 109(5):E242-E251.
53. Vigneron F., Dos S.P., Lemoine S., Bonnet M., Tariosse L., Couffinhal T., et al. GSK-3beta at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc Res 2011, 90:49-56.
54. Naoum J.J., Zhang S., Woodside K.J., Song W., Guo Q., Belalcazar L.M., et al. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and simvastatin. Surgery 2004, 136:323-328.
55. McCormick M.E., Goel R., Fulton D., Oess S., Newman D., Tzima E. Platelet-endothelial cell adhesion molecule-1 regulates endothelial NO synthase activity and localization through signal transducers and activators of transcription 3-dependent NOSTRIN expression. Arterioscler Thromb Vasc Biol 2011, 31:643-649.
56. Zimmermann K., Opitz N., Dedio J., Renne C., Muller-Esterl W., Oess S. NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2002, 99:17167-17172.
57. Haghikia A., Missol-Kolka E., Tsikas D., Venturini L., Brundiers S., Castoldi M., et al. Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J 2011, 32:1287-1297.
58. Bolli R. The late phase of preconditioning. Circ Res 2000, 87:972-983.
59. Xi L., Jarrett N.C., Hess M.L., Kukreja R.C. Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice. Circulation 1999, 99:2157-2163.
60. Xuan Y.T., Guo Y., Zhu Y., Wang O.L., Rokosh G., Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription 1/3 pathway. Circulation 2007, 116:535-544.